SGLT2 inhibitor dapagliflozin treats heart failure with preserved ejection fraction via the SIRT1/PGC-1α pathway
Acta Biochimica et Biophysica Sinica · 2026
DOI: 10.3724/abbs.2026078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biochimica et Biophysica Sinica, 2026. Verfasst von Shiwen Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, China. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Heart Failure, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, China.
- Department of General Medicine, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
- National Key Laboratory for Innovation and Transformation of Luobing Theory; The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and C…
- Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
- Department of Cardiology, Fengxian People's Hospital, Xuzhou 221700, China.
- Clinical Medical Institute, Xinjiang Medical University, Urumqi 830000, China.
Zitieren
APA
Zhang, S., Cui, Y., Chen, J., Zhou, S., Zhang, Y., Li, K., & Hou, Y. (2026). SGLT2 inhibitor dapagliflozin treats heart failure with preserved ejection fraction via the SIRT1/PGC-1α pathway. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2026078
Vancouver
Zhang S, Cui Y, Chen J, Zhou S, Zhang Y, Li K, et al. SGLT2 inhibitor dapagliflozin treats heart failure with preserved ejection fraction via the SIRT1/PGC-1α pathway. Acta Biochimica et Biophysica Sinica. 2026. doi:10.3724/abbs.2026078
BibTeX
@article{Zhang2026,
author = {Zhang, Shiwen and Cui, Yansong and Chen, Jingwen and Zhou, Shuaishuai and Zhang, Yujiao and Li, Kuan and Hou, Yinglong},
title = {SGLT2 inhibitor dapagliflozin treats heart failure with preserved ejection fraction via the SIRT1/PGC-1α pathway},
journal = {Acta Biochimica et Biophysica Sinica},
year = {2026},
doi = {10.3724/abbs.2026078}
}
EUVIMED